+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eukaryotic Translation Initiation Factor 4E"

Eukaryotic Translation Initiation Factor 4E Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Eukaryotic Translation Initiation Factor 4E Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 36 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The Eukaryotic Translation Initiation Factor 4E (eIF4E) market is a subset of the Central Nervous System (CNS) Drugs market. It is composed of drugs that target eIF4E, a protein involved in the translation of mRNA into proteins. These drugs are used to treat a variety of CNS disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. They are also used to treat neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). eIF4E drugs are typically administered orally or intravenously, and they are often used in combination with other drugs. They are designed to target specific proteins in the brain, and they are often used in combination with other drugs to maximize their effectiveness. The eIF4E market is highly competitive, with many companies developing and marketing drugs targeting eIF4E. Some of the major players in the market include AbbVie, AstraZeneca, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more